Treatment with the IL-1Ra, anakinra, proved efficient in reducing neutrophilic inflammation at the peak of viral replication while blocking of IL-17A abrogated neutrophilia in the early phase of viral infection. This evidence concerns the gene IL17A and viral infectious disease.